Rigel Pharmaceuticals appoints Alison Hannah as EVP, CMO; Lisa Rojkjaer departs

RIGEL PHARMACEUTICALS INC

Alison L. Hannah, M.D. appointed Executive Vice President and Chief Medical Officer effective July 1, 2026.
Dr. Hannah resigned from the Board of Directors effective July 1, 2026; she had served as a board member since May 2021.
Lisa Rojkjaer, M.D. ceased as EVP and CMO and separated from the company effective June 25, 2026.
Dr. Hannah previously served as CMO of CytomX Therapeutics and as a consultant to the pharmaceutical and biotechnology industry.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Alison L. Hannah

Director

RIGL · RIGEL PHARMACEUTICALS INC

Effective: 2026-07-01
Filed: July 1, 2026, 4:11 PM ET

In connection with her appointment, Dr. Hannah resigned from the Company’s Board of Directors (the “Board”), effective July 1, 2026.

Appointed

Alison L. Hannah

Executive Vice President and Chief Medical Officer

RIGL · RIGEL PHARMACEUTICALS INC

Effective: 2026-07-01
Filed: July 1, 2026, 4:11 PM ET

On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company.

Departed

Lisa Rojkjaer

Executive Vice President and Chief Medical Officer

RIGL · RIGEL PHARMACEUTICALS INC

Effective: 2026-06-25
Filed: July 1, 2026, 4:11 PM ET

Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alison L. Hannah resigned as Director at RIGEL PHARMACEUTICALS INC.

Action: resigned
Role: Director

Exact text from the filing

In connection with her appointment, Dr. Hannah resigned from the Company’s Board of Directors (the “Board”), effective July 1, 2026.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alison L. Hannah was appointed as Executive Vice President and Chief Medical Officer at RIGEL PHARMACEUTICALS INC.

Action: appointed
Role: Executive Vice President and Chief Medical Officer

Exact text from the filing

On July 1, 2026, Rigel Pharmaceuticals, Inc. (the "Company") announced that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lisa Rojkjaer departed as Executive Vice President and Chief Medical Officer at RIGEL PHARMACEUTICALS INC.

Action: ceased serving
Role: Executive Vice President and Chief Medical Officer

Exact text from the filing

Effective June 25, 2026, Lisa Rojkjaer, M.D. ceased serving as Executive Vice President and Chief Medical Officer of the Company and separated from the Company.

View on SEC.gov

RIGEL PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001034842-26-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.